New Disease-Modifying Agents in Clinical Trials for Rheumatoid Arthritis
The provided evidence does not contain specific information about new disease-modifying agents currently in phase 2 or phase 3 clinical trials for rheumatoid arthritis. The guidelines and research articles focus on established therapies rather than investigational agents.
What the Evidence Shows
Current Standard Approaches for Your Scenario
For a patient on methotrexate 20-25 mg weekly plus prednisolone 10 mg daily with ongoing erosive progression, the established approach is to add a biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD) rather than waiting for investigational agents 1.
The 2020 EULAR guidelines emphasize that:
- Methotrexate remains the anchor drug and should be continued when adding advanced therapies 1
- Multiple successive drug options are often needed to reach therapeutic goals
- The therapeutic spectrum currently available can bring the vast majority of patients into remission or low disease activity 1
Available Approved Options (Not Investigational)
The 2021 ACR guidelines 2 and 2020 EULAR recommendations 1 discuss:
- TNF inhibitors (first biologic class introduced, still widely used)
- Other bDMARDs (non-TNF biologics)
- Targeted synthetic DMARDs (JAK inhibitors)
Recent Phase 4 evidence confirms that TNF inhibitors remain clinically relevant in MTX-resistant disease, with newer biologics and targeted synthetic DMARDs showing comparable efficacy 3.
Clinical Trial Landscape Gap
The evidence provided includes:
- One mention of efzofitimod (targeting neuropilin-2) that showed steroid-reducing effects in Phase IIb but not Phase III trials—though this was for sarcoidosis, not RA 4
- JAK inhibitors accumulating evidence across presentations 4, but these are already approved agents, not investigational
Practical Recommendation
Rather than waiting for investigational agents, escalate therapy now by adding an approved bDMARD or tsDMARD to the existing methotrexate regimen. Continuing current therapy while erosive disease progresses risks irreversible joint damage and disability 1.
Common Pitfall to Avoid
Do not delay treatment escalation in a patient with documented erosive progression. The evidence consistently shows that early, aggressive treatment prevents irreversible structural damage. Waiting for investigational agents to complete trials (which may take years) allows preventable joint destruction to occur.